36,000 bottles of eye drops recalled after printer ink is found inside

 

James Legge
Thursday 03 January 2013 18:36
Comments
Almost 36,000 bottles of prescription eye drops need to be sent back to their manufacturer
Almost 36,000 bottles of prescription eye drops need to be sent back to their manufacturer

Almost 36,000 bottles of prescription eye drops need to be sent back to their manufacturer, after they were found to contain printing ink.

Bausch and Lomb, the maker of the drops, has sent letters to doctors and chemists ordering the return of 1,780 batches, each containing 20 bottles of the solution, which is used as a local anaesthetic for eye procedures in hospitals.

A spokeswoman for the company said: “Bausch and Lomb is conducting a voluntary recall of a single lot of proxymetacaine 0.5 per cent Minims Eye Drops Solution.

“We chose to initiate this recall after confirming a report of the presence of foreign particles in a product from this single lot.

“No other products in the Minims range or other Bausch and Lomb products are affected by this action.”

There is so far no evidence of injury to users as a result of the blunder.

In a letter to hospitals and pharmacies, Irene Fazakerley, from the Scottish Government's health department, said: “Bausch and Lomb is recalling the batch because black particles have been identified in some packs.

“Initial investigations suggest that the contaminant is printing ink, in which case we understand that the risk of toxicity is low.

“No other batches of this or any other product are affected.

“Healthcare professionals are asked to quarantine remaining stock and contact the wholesaler from which it was obtained to arrange uplift and replacement.”

A spokesman from the drug watchdog, the Medicines and Healthcare products Regulatory Agency said: “These eye drops are only used in hospitals and administered by medical professionals.

“We don't anticipate that people will have them at home.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in